Build Generational Wealth with
AlphaMadera's AI-Driven Investment Intelligence

Institutional-grade analytics, real-time data, and AI research tools — built for investors who think in decades, not days.

Ask Compass anything about the market — earnings, filings, or strategy — in plain English.

Real-time institutional data AI that reads filings & transcripts Built for decades, not days
or search any ticker above
Editorial illustration: PRIMARY SUBJECT — this editorial photo illustrates a story about SPDR Gold Shares, a Asset Management company in the Fin
AlphaBlog

Gold Jumps, Oil Shrugs, Message Matters

A 2.6% surge in gold while crude eases is not a clean inflation trade. It looks more like a market hedging policy and geopolitical uncertainty while growth-sensitive signals stay mixed.

Read more →

Market News

Fidus Investment: Too Expensive To Buy Before Earnings (Earnings Preview)

Fidus Investment: Too Expensive To Buy Before Earnings (Earnings Preview)

FDUS remains a hold as recent price appreciation limits upside, despite strong Q1 results and robust dividend coverage. FDUS's portfolio is well-structured, with a significant first-lien debt focus and resilient software/IT exposure, supported by high switching costs and sponsor backing. NII growth of 22.5%, 151% regular DPS coverage, and minimal non-accruals underscore FDUS's superior performance versus BDC peers.

Aug 05, 2026 11:33 AM seekingalpha.com
Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

Astrana Health outperformed as the company results have continued to demonstrate that it was not taking advantage of loopholes within Medicare coding. Magnolia Oil & Gas saw shares decline after an agreement was reached to end the war between the US and Iran and reopen the Strait of Hormuz. We initiated a position in Insteel Industries, the nation's largest manufacturer of steel wire reinforcing products for concrete construction.

Aug 05, 2026 10:05 AM seekingalpha.com
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics remains a "Buy," driven by progress on zorevunersen for SCN1A Dravet Syndrome and robust clinical milestones ahead. The company expects an FDA meeting in H2 2026, rolling NDA submission in Q1 2027, and phase 3 EMPEROR data in Q3 2027 for zorevunersen. The advancement of STK-002 for autosomal dominant optic atrophy in the phase 1 OSPREY study showcases the TANGO platform's broader therapeutic potential.

Aug 05, 2026 09:50 AM seekingalpha.com
Match: No AI-Driven Makeover Can Save This Company

Match: No AI-Driven Makeover Can Save This Company

Match Group faces persistent declines in its payer base, with only Hinge showing growth that fails to offset Tinder's losses. I maintain a sell rating on MTCH, as recent Q2 results reinforce concerns over shrinking users and limited success from AI-driven initiatives. MTCH's ambitious AI and Tinder redesign efforts appear risky, with little evidence they will reverse user attrition or drive meaningful revenue growth.

Aug 05, 2026 08:40 AM seekingalpha.com

Stock News